Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers

Abstract

OBJECTIVE:

To evaluate the toxicity and tolerability of the Intraperitoneal/Intravenous (IP/IV) regimen utilized at Moffitt Cancer Center and to compare our findings with the IP, Gynecologic Oncology Group (GOG) study 172.

STUDY DESIGN:

Using the Moffitt database, we evaluated the outcomes of patients who underwent primary optimal cytoreduction for stage IIC-IV, epithelial ovarian, tubal, and peritoneal carcinoma followed by the intent to treat with IP/IV chemotherapy. NCI CTCAE v3.0 was used to grade adverse events.

RESULTS:

We identified 69 patients meeting our inclusion criteria from 2006 - 2011. The most frequent grade 3/4 toxicities were neutropenia (48%), gastrointestinal (9%), metabolic (9%), and infection (5%). Remaining toxicities occurred in < 5% of patients. Patients received a greater number of cycles compared to GOG 172 (4.28 vs. 3.66, respectively, p = 0.0088).

CONCLUSION:

Through the use of supportive care and the preemptive management of established side effects, the associated toxicities and tolerability of IP chemotherapy appear improved.